**Letter for community pharmacies**

Practice Name and Address

DATE

**Please ensure that all pharmacy staff, including locums,**

**have read this letter and it is retained for your records.**

Dear Pharmacist

**Re: Switch from Fostair**® **to Luforbec**® **or Bibecfo**®

(**Insert name of practice here**) has agreed to switch all **Fostair**® **Metered Dose Inhaler (MDI) for adult patients to Luforbec**® **MDI or Bibecfo**® **MDI.** This change is supported by theICS Respiratory Group which includes Respiratory Specialists from NUH and SFH, and Community, Primary Care and patient representation and endorsed by the Nottingham and Nottinghamshire ICB. I am therefore writing to inform you that patients will be switched from (insert date here).

All patients affected by the change will receive an information leaflet explaining the reason for the switch. However, we would also be grateful if, when a patient receives their Luforbec® or Bibecfo® inhaler for the first time, the change in inhaler can be highlighted by you, to avoid any confusion.

I hope this information allows you to manage your stock levels of Fostair®, Luforbec® and Bibecfo® appropriately and to manage any questions from patients.

Thank you in advance for your help with this matter.

Yours sincerely,

Xxxxx Surgery